Chemo after surgery for high-risk stage III colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk stage III colon adenocarcinoma (pT4N1 or any T with N2).
- Your colon tumor was fully removed with surgery (R0 resection) within 60 days.
- No distant spread (no metastasis) and no need for radiation because of middle/lower rectal cancer.
- You are able to take chemotherapy: blood counts and liver/kidney tests are high enough.
- You can sign consent, and your health allows an estimated 5-year life expectancy or more.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment approach for people with certain high-risk colon cancers (stage II or III in the upper colon) after surgery. It aims to see if adding a study drug can help prevent the cancer from coming back.
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
This trial checks whether a special blood test (ctDNA methylation) can help decide the best chemotherapy after surgery for people at higher risk of colon cancer coming back. It may help spare some patients unnecessary treatment while aiming to improve outcomes for those likely to relapse.
This trial studies whether adding chemotherapy after surgery helps people with colon cancer that was diagnosed before surgery as stage III and later found to be without certain high-risk features. It may help lower the chance the cancer comes back, but you must meet specific surgery and health criteria.
This Phase 3 trial studies whether adding targeted therapy to standard chemotherapy after surgery helps people with stage T3-4, N2 colon cancer live longer or have fewer cancer returns. You would be assigned to receive chemotherapy with targeted therapy or chemotherapy alone, based on the study plan.
Hear when a new Colon Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.